全文获取类型
收费全文 | 252213篇 |
免费 | 14550篇 |
国内免费 | 7242篇 |
专业分类
耳鼻咽喉 | 3378篇 |
儿科学 | 8552篇 |
妇产科学 | 3095篇 |
基础医学 | 17967篇 |
口腔科学 | 6237篇 |
临床医学 | 29881篇 |
内科学 | 43701篇 |
皮肤病学 | 3194篇 |
神经病学 | 13226篇 |
特种医学 | 20787篇 |
外国民族医学 | 42篇 |
外科学 | 36138篇 |
综合类 | 23081篇 |
现状与发展 | 29篇 |
预防医学 | 15037篇 |
眼科学 | 7317篇 |
药学 | 24392篇 |
87篇 | |
中国医学 | 4566篇 |
肿瘤学 | 13298篇 |
出版年
2023年 | 2657篇 |
2022年 | 4723篇 |
2021年 | 10696篇 |
2020年 | 6564篇 |
2019年 | 12435篇 |
2018年 | 7129篇 |
2017年 | 6230篇 |
2016年 | 8107篇 |
2015年 | 11053篇 |
2014年 | 19994篇 |
2013年 | 17227篇 |
2012年 | 20452篇 |
2011年 | 17354篇 |
2010年 | 15848篇 |
2009年 | 15556篇 |
2008年 | 14209篇 |
2007年 | 14331篇 |
2006年 | 12184篇 |
2005年 | 8306篇 |
2004年 | 4579篇 |
2003年 | 3900篇 |
2002年 | 3214篇 |
2001年 | 2562篇 |
2000年 | 2270篇 |
1999年 | 1514篇 |
1998年 | 1824篇 |
1997年 | 1734篇 |
1996年 | 1508篇 |
1995年 | 1516篇 |
1994年 | 1464篇 |
1993年 | 1130篇 |
1992年 | 1298篇 |
1991年 | 1157篇 |
1990年 | 1182篇 |
1989年 | 1157篇 |
1988年 | 1060篇 |
1987年 | 961篇 |
1986年 | 764篇 |
1985年 | 1705篇 |
1984年 | 1864篇 |
1983年 | 1330篇 |
1982年 | 1459篇 |
1981年 | 1414篇 |
1980年 | 1211篇 |
1979年 | 1032篇 |
1978年 | 782篇 |
1977年 | 789篇 |
1976年 | 681篇 |
1974年 | 454篇 |
1973年 | 432篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
81.
82.
83.
《Drug discovery today》2022,27(1):246-256
Bromodomain-containing protein 4 (BRD4) is emerging as a therapeutic target that acts synergistically with other targets of small-molecule drugs in cancer. Therefore, the discovery of potential new dual-target inhibitors of BRD4 may be a promising strategy for cancer therapy. In this review, we highlight a series of strategies to design therapeutic dual-target inhibitors of BRD4 that focus on the synergistic functions of this protein. Drug combinations that exploit synthetic lethality, protein–protein interactions, functional complementarity, and blocking of resistance mechanisms could ultimately overcome the barriers inherent to the development of BRD4 inhibitors as future cancer drugs. 相似文献
86.
87.
88.
89.
《Cirugía espa?ola》2022,100(11):709-717
ObjectiveMost evidence, including recent randomized controlled trials, analysing anal squamous cell carcinoma (SCC) do not consider immunocompromise patient population. The aim of this study was to compare clinical and oncological outcomes among immunocompetent and immunocompromised patients with anal squamous cell carcinoma.MethodMulticentric retrospective comparative study including 2 cohorts of consecutive patients, immunocompetent and immunocompromised, diagnosed with anal SCC. This study evaluated clinical characteristics, clinical response to radical chemoradiotherapy (CRT) and long-term oncological results including both local and distant recurrence, overall survival (OS) and disease-free survival (DFS).ResultsA total of 84 patients, 47 (55.6%) female, diagnosed with anal SCC from January 2012 to December 2017 were included, 22 (26%) and 62 (74%) patients in immunocompromised and immunocompetent groups respectively. Patients in immunocompromised group were significantly younger (53 vs. 61 years; P=0.001), with smaller tumoral size (P=0.044) and reported higher rates of substance abuse.including tobacco use (P=0.034) and parenteral drug consumption (P=0.001). No differences were found in administered therapies (P=301) neither in clinical response to chemoradiotherapy (83 vs. 100%). Moreover, similar 5-year OS (60 vs. 64%; P=0.756) and DFS (65 vs. 68%; P=0.338) were observed.ConclusionThe present study shows no significant differences in long-term oncological results among immunocompetent and immunocompromised patients diagnosed with anal SCC, with a similar oncologic treatment. This evidence might be explained due to the close monitoring and adequate therapeutic control of HIV positive patients. 相似文献